Danaher Corporation $DHR Shares Sold by Duncker Streett & Co. Inc.

Key Points

• Duncker Streett & Co. Inc. reduced its stake in Danaher Corporation by 2.5% during the 2nd quarter, now holding 49,946 shares valued at approximately $9.87 million.
• Danaher reported a Q2 EPS of $1.80, beating analysts' estimates by $0.16, with revenues of $5.94 billion, which is a 3.4% increase from the previous year.
• The company declared a quarterly dividend of $0.32 per share, yielding 0.6%, payable to shareholders on October 31st.

Duncker Streett & Co. Inc. lessened its stake in Danaher Corporation (NYSE:DHR - Free Report) by 2.5% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 49,946 shares of the conglomerate's stock after selling 1,277 shares during the quarter. Danaher accounts for about 1.8% of Duncker Streett & Co. Inc.'s portfolio, making the stock its 13th largest holding. Duncker Streett & Co. Inc.'s holdings in Danaher were worth $9,866,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Nuveen LLC purchased a new position in shares of Danaher in the 1st quarter valued at about $833,941,000. Invesco Ltd. increased its stake in shares of Danaher by 44.5% in the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Baird Financial Group Inc. increased its stake in shares of Danaher by 290.6% in the 1st quarter. Baird Financial Group Inc. now owns 1,441,706 shares of the conglomerate's stock valued at $295,550,000 after purchasing an additional 1,072,617 shares in the last quarter. Generation Investment Management LLP increased its stake in shares of Danaher by 33.2% in the 1st quarter. Generation Investment Management LLP now owns 3,178,124 shares of the conglomerate's stock valued at $651,515,000 after purchasing an additional 791,662 shares in the last quarter. Finally, Parnassus Investments LLC increased its stake in shares of Danaher by 23.3% in the 1st quarter. Parnassus Investments LLC now owns 3,828,024 shares of the conglomerate's stock valued at $784,745,000 after purchasing an additional 722,636 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Stock Up 0.5%

NYSE:DHR opened at $206.19 on Wednesday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock's fifty day moving average is $200.96 and its two-hundred day moving average is $197.13. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.41. The stock has a market capitalization of $147.64 billion, a price-to-earnings ratio of 43.87, a price-to-earnings-growth ratio of 2.92 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the firm earned $1.72 earnings per share. The firm's revenue was up 3.4% compared to the same quarter last year. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be paid a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date is Friday, September 26th. Danaher's dividend payout ratio is 27.23%.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the company's stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 11.20% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research analyst reports. Redburn Partners set a $220.00 target price on Danaher in a report on Wednesday, October 8th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a report on Friday, July 11th. Rothschild Redb cut Danaher from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 8th. Wall Street Zen upgraded Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Finally, Guggenheim restated a "buy" rating and issued a $250.00 price target on shares of Danaher in a research report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $244.60.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.